Form 4: C4 Therapeutics Director Boosts Stake

C4 Therapeutics Director Kenneth Anderson acquired 5,349 shares of common stock at $2.15 per share, opting for equity in lieu of cash compensation.

Summary

• Kenneth Anderson, a Director of C4 Therapeutics, Inc. (CCCC), acquired 5,349 shares of common stock.
• The transaction occurred on October 1, 2025, with shares priced at $2.15 each, based on the closing market price.
• These shares were issued as part of the company's Non-Employee Director Compensation Policy, where Mr. Anderson elected to receive equity instead of cash for his services.
• Following this transaction, Mr. Anderson directly beneficially owns 140,574 shares of common stock.
• Indirect beneficial ownership includes 47,316 shares held by his spouse, 61,265 shares by the Kenneth C. Anderson 2016 Grantor Retained Annuity Trust, 61,265 shares by the Cynthia E. Anderson 2016 Grantor Retained Annuity Trust, 16,939 shares by the Kenneth C. Anderson 2015 Irrevocable Trust, and 16,939 shares by the Cynthia E. Anderson 2015 Irrevocable Trust.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as a director is increasing their equity stake, signaling confidence in the company's future, even if it's part of a compensation plan. It's a routine transaction but still a positive signal.

Positives

• A director choosing to receive equity over cash compensation can signal confidence in the company's future performance.
• The acquisition increases the director's alignment with shareholder interests.

Future Outlook

N/A

Industry Context

This is a routine insider transaction and does not provide specific industry context or trends. It reflects an individual director's compensation choice within the biotechnology sector.

Stakeholder Impact

• Shareholders: Potentially positive signal of director confidence and alignment of interests.
• Management: Reinforces the company's compensation policy for non-employee directors.

Key Dates

Recommendation

This Form 4 filing indicates a routine insider transaction where a director opted for equity compensation. While it signals confidence, the transaction size is not substantial enough, nor does the filing contain new material information, to warrant a change in investment recommendation based solely on this report. It's a minor positive signal, but not a catalyst for a 'buy' or 'sell' decision.

Keywords

C4 Therapeutics, CCCC, Insider Trading, Form 4, Director Compensation, Equity Compensation, Stock Acquisition, Kenneth Anderson